Larsucosterol
- Generic Name
- Larsucosterol
- Drug Type
- Small Molecule
- Chemical Formula
- C27H46O5S
- CAS Number
- 884905-07-1
- Unique Ingredient Identifier
- UGX2V7MGMZ
Larsucosterol Shows Promising 90-Day Mortality Reduction in Phase 2b Alcohol-Associated Hepatitis Trial
• Phase 2b AHFIRM trial results published in NEJM Evidence demonstrate larsucosterol reduced 90-day mortality by up to 41% in alcohol-associated hepatitis patients compared to placebo.
• U.S. patient subgroup analysis revealed even more substantial mortality reductions of 57-58% with both 30mg and 90mg doses, showing strong statistical significance.
• The drug demonstrated a favorable safety profile with treatment-emergent adverse events comparable to placebo, marking a potential breakthrough for a condition with no FDA-approved therapies.
Evorpacept Shows Promise in HER2-Positive Gastric Cancer: Updated ASPEN-06 Data
• ALX Oncology's ASPEN-06 Phase 2 trial evaluates evorpacept, a CD47-blocker, in HER2-positive advanced gastric cancer patients who have been previously treated.
• Updated data from the ASPEN-06 trial were presented at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI).
• The virtual event hosted by ALX Oncology on January 23, reviewed the ASPEN-06 data, focusing on evorpacept's potential in immuno-oncology.
• The ASPEN-06 trial is a phase 2/3 study of evorpacept in patients with HER2-overexpressing gastric/gastroesophageal cancer.
Alcoholic Hepatitis Pipeline Insights 2024: Emerging Therapies and Market Prospects
The 2024 Alcoholic Hepatitis Pipeline report highlights significant advancements in treatment therapies, with over 10 companies developing innovative solutions. Key developments include Breakthrough Therapy designation for larsucosterol and progress in Aldeyra Therapeutics' RASP modulator platform. The report provides a comprehensive overview of the clinical development scenario, therapeutic assessments, and market dynamics.
DURECT's Larsucosterol Shows Promise in Alcohol-Associated Hepatitis Treatment
• DURECT Corporation's larsucosterol demonstrates potential in treating alcohol-associated hepatitis (AH) by reducing mortality rates in U.S. patients.
• A Phase 3 trial, agreed upon with the FDA, will assess larsucosterol's efficacy with a 90-day survival primary endpoint, aiming for topline data within two years.
• Larsucosterol targets DNA methyltransferases, epigenetic enzymes linked to hypermethylation in AH, offering a novel approach to managing the condition.
• Data from the AHFIRM Phase 2b trial supports the Phase 3 design, showing significant mortality reduction with larsucosterol in U.S. patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath